Agriculture-based exchange-traded funds (ETFs) can provide investors with portfolio diversification and a low-cost way to create a passive income stream.
A high-profile clinical failure by a rival is weighing on the drugmaker's shares today.
Novartis expects to submit regulatory applications for its biosimilar soon.
Two big companies that are worth investing in have low share prices but big dividends.
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group...
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.